Sign In
Buy MBRX
$2.46
+0 (+0%)
At Close: Jun 03, 2026
Moleculin to Participate in Panel at ROTH Capital's "COVID-19 Therapeutics in Development" Healthcare Event
07:30am, Tuesday, 27'th Oct 2020
HOUSTON, Oct. 27, 2020 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting s
Moleculin Biotech (MBRX) Investor Presentation - Slideshow
07:03pm, Wednesday, 02'nd Sep 2020
The following slide deck was published by Moleculin Biotech, Inc. in conjunction with this event..
Moleculin Biotech, Inc. Reports Financial Results for the Quarter Ended June 30, 2020
11:30am, Wednesday, 12'th Aug 2020
Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, ann
Here's Why We're A Bit Worried About Moleculin Biotech's (NASDAQ:MBRX) Cash Burn Situation
01:13pm, Tuesday, 11'th Aug 2020
We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...
Moleculin Biotech (MBRX) Gets a Buy Rating from Maxim Group - Markets
03:30pm, Wednesday, 22'nd Jul 2020
In a report released yesterday, Jason McCarthy from Maxim Group assigned a Buy rating to Moleculin Biotech (MBRX – Research
Dow, S&P close higher as Covid-battered stocks surge, but off session’s best levels as tech sector sinks
09:24pm, Tuesday, 21'st Jul 2020
U.S. stock-indexes finish mostly higher Tuesday, but off the session’s best levels, as investors snap up beaten-down energy and financial stocks amid a slate...
Coronavirus update: U.S. case tally climbs above 3.8 million; President Trump appears to have changed his view on face masks
08:11pm, Tuesday, 21'st Jul 2020
The number of confirmed cases of the coronavirus illness COVID-19 in the U.S. rose above 3.8 million on Tuesday, and President Donald Trump appeared to...
Moleculin Pops 33% On Anti-Viral Activity For Potential Covid-19 Treatment
01:59pm, Tuesday, 21'st Jul 2020
Moleculin Biotech (MBRX) on Tuesday announced that a second round of independent laboratory testing has confirmed the antiviral activity of its drug candidate WP1122 as a potential treatment against c
Moleculin Shares Jump on Progress With Virus-Drug Candidate
01:36pm, Tuesday, 21'st Jul 2020
Moleculin Biotech says independent testing confirms the antiviral activity of its coronavirus treatment candidate.
Moleculin Biotech says second lab test found antiviral activity for potential COVID-19 treatment
12:30pm, Tuesday, 21'st Jul 2020
Shares of small-cap Moleculin Biotech Inc. undefined soared 43% in premarket trade Tuesday, after the company said a second round of laboratory testing...
Moleculin Biotech says second lab test found antiviral activity for potential COVID-19 treatment
11:46am, Tuesday, 21'st Jul 2020
Shares of small-cap Moleculin Biotech Inc. soared 43% in premarket trade Tuesday, after the company said a second round of laboratory testing confirmed antiviral activity for WP1122, its candidate as
Moleculin Announces New Independent In Vitro Testing Confirms Antiviral Activity of WP1122 in Coronavirus
11:30am, Tuesday, 21'st Jul 2020
Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses,
Moleculin Biotech (NASDAQ:MBRX) Shares Gap Down to $1.07
01:54am, Sunday, 19'th Jul 2020
Moleculin Biotech Inc (NASDAQ:MBRX) shares gapped down before the market opened on Friday . The stock had previously closed at $1.11, but opened at $1.07. Moleculin Biotech shares last traded at $1.03
Moleculin Biotech (MBRX) Gets a Buy Rating from Maxim Group - Markets
05:06pm, Thursday, 16'th Jul 2020
In a report released yesterday, Jason McCarthy from Maxim Group assigned a Buy rating to Moleculin Biotech (MBRX – Research
Moleculin Surges on Manufacturing Deal for Coronavirus Therapy
03:11pm, Thursday, 16'th Jul 2020
Moleculin (MBRX) signs an agreement with Sterling Pharma Solutions for manufacturing and supply of WP1122, which is being developed as potential treatment for COVID-19.
